Drug maker pulls off rare feat — literally — with 1st drug approval

The North Bay company was started just seven years ago, went public nearly three years ago and on Wednesday landed FDA approval of its first drug, a treatment for a ultra-rare disease known as MPS VII that will cost $375,000 a year.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news